Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma

Virginia Di Paolo, Ida Russo, Renata Boldrini, Lucilla Ravà, Marco Pezzullo, Maria Chiara Benedetti, Angela Galardi, Marta Colletti, Rossella Rota, Domenico Orlando, Alessandro Crocoli, Hector Peinado, Giuseppe Maria Milano, Angela Di Giannatale

Research output: Contribution to journalArticle

Abstract

BACKGROUND: The Intratumoral Microvessel Density (IMVD) is commonly used to quantify tumoral vascularization and is usually assessed by pan-endothelial markers, such as CD31. Endoglin (CD105) is a protein predominantly expressed in proliferating endothelium and the IMVD determined by this marker measures specifically the neovascularization. In this study, we investigated the CD105 expression in pediatric rhabdomyosarcoma and assessed the neovascularization by using the angiogenic ratio IMVD-CD105 to IMVD-CD31.

METHODS: Paraffin-embedded archival tumor specimens were selected from 65 pediatric patients affected by rhabdomyosarcoma. The expression levels of CD105, CD31 and Vascular Endothelial Growth Factor (VEGF) were investigated in 30 cases (18 embryonal and 12 alveolar) available for this study. The IMVD-CD105 to IMVD-CD31 expression ratio was correlated with clinical and pathologic features of these patients.

RESULTS: We found a specific expression of endoglin (CD105) in endothelial cells of all the rhabdomyosarcoma specimens analyzed. We observed a significant positive correlation between the IMVD individually measured by CD105 and CD31. The CD105/CD31 expression ratio was significantly higher in patients with lower survival and embryonal histology. Indeed, patients with a CD105/CD31 expression ratio < 1.3 had a significantly increased OS (88%, 95%CI, 60%-97%) compared to patients with higher values (40%, 95%CI, 12%-67%). We did not find any statistical correlation among VEGF and EFS, OS and CD105/CD31 expression ratio.

CONCLUSION: CD105 is expressed on endothelial cells of rhabdomyosarcoma and represent a useful tool to quantify neovascularization in this tumor. If confirmed by further studies, these results will indicate that CD105 is a potential target for combined therapies in rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)31
Number of pages11
JournalBMC Cancer
Volume18
Issue number1
DOIs
Publication statusPublished - Jan 5 2018

    Fingerprint

Keywords

  • Adolescent
  • Biomarkers, Tumor/genetics
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Endoglin/genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Neovascularization, Pathologic/genetics
  • Platelet Endothelial Cell Adhesion Molecule-1/genetics
  • Rhabdomyosarcoma/genetics
  • Vascular Endothelial Growth Factor A/genetics

Cite this